CHMP News – February 2016
Six medicines, including two orphan medicines, recommended for approval
At its February 2016 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended six new medicines for marketing authorisation.
The CHMP recommended granting marketing authorisations for two medicines for the prevention and treatment of bleeding in patients with haemophilia B, Alprolix (eftrenonacog alfa) and Idelvion (albutrepenonacog alfa). Both these medicines have anorphan designation.
Lonsurf (trifluridine / tipiracil) was recommended by the CHMP for the treatment of metastatic colorectal cancer.
Descovy (emtricitabine / tenofovir alafenamide) received a positive opinion for the treatment of HIV infection.
The CHMP recommended granting a marketing authorisation for Taltz (ixekizumab) for the treatment of plaque psoriasis.
The generic medicine Palonosetron Hospira (palonosetron) received a positive recommendation from the Committee for the prevention of nausea and vomiting associated with chemotherapy.
Seven recommendations on extensions of therapeutic indications
The Committee recommended extensions of indications for Giotrif, Humira, Ruconest,TachoSil, Zydelig and two extensions of indications for Opdivo.
Start of review: medicines containing dienogest and ethinylestradiol
The CHMP started a review of medicines containing dienogest 2 mg and ethinylestradiol 0.03 mg when used for acne. These products are available in several countries in the European Union (EU) as oral contraceptives and for the treatment of moderate acne in women. More information is available on HALMED's website.
Outcome of review on SGLT2 inhibitors: recommendations to minimise risk of diabetic ketoacidosis
The CHMP confirmed recommendations from the Pharmacovigilance Risk Assessment Committee (PRAC) to minimise the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors (a class of type 2 diabetes medicines). More information is available on HALMED's website.
CHMP confirms recommendations to minimise risk of the brain infection PML with Tysabri
EMA’s scientific review of the known risk of progressive multifocal leukoencephalopathy (PML) with the multiple sclerosis medicine Tysabri (natalizumab) is now completed, with the CHMP confirming the PRAC recommendations aimed at minimising this risk. More information is available on HALMED's website.
PRIME and early access tools
The CHMP adopted the final document on PRIME, a new scheme to support the development of medicines addressing unmet medical needs, as well as revised guidelines on the implementation of accelerated assessment and conditional marketing authorisation. These documents will be published on the EMA website in early March.
More information on the CHMP's January 2016 meeting can be found here.